ABIOMED, Inc. (Nasdaq:ABMD)
April 16th, 2019
Amidst rising markets ABIOMED, Inc. fell ($6.35) Tuesday, down 2.33%, closing at $265.95. As well as the drop in value, ABIOMED, Inc. hit a new 52 week low of $264.54, breaking the previous low of $267.60 from earlier this month. The next earnings report is expected in approximately 16 days.
Forecasts from 10 analysts points to the possibility that ABIOMED, Inc. might go up significantly (55.89%), while Finbox has calculated (with low uncertainty) a fair value price of $207.53.
The market sectors were mixed Tuesday with a majority of the sectors trending up. Financials saw the biggest increase of the day (1.37%), while Real Estate saw the biggest drop (-2.38%). Information Technology has seen the biggest year-to-date gain at 23.78%.
Energy saw the biggest turnaround from its 5-day performance of -1.22%, as it went up 0.64%. Real Estate and Utilities experienced turn arounds from their five day positive performance, Real Estate with a drop of -2.38%.
- Financials went up with a 1.37% change.
- Energy went up with a 0.64% change.
- Industrials went up with a 0.59% change.
- Information Technology went up with a 0.49% change.
- Consumer Discretionary went up with a 0.48% change.
- Materials went up with a 0.47% change.
- Communication Services went up with a 0.21% change.
- Consumer Staples went down with a -0.06% change.
- Utilities went down with a -1.39% change.
- Healthcare went down with a -2.03% change.
- Real Estate went down with a -2.38% change.
ABIOMED, Inc. Info
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.